Thank you for joining

The Impact of the COVID-19 Pandemic on Viral Hepatitis
Presented by HepVu

Subscribe to HepVu’s newsletter and blog updates: www.hepvu.org/email-signup/

The webinar will begin at 12:00 PM EST
The Impact of the COVID-19 Pandemic on Viral Hepatitis

Presented by HepVu

June 2, 2020
Webinar Objectives

I. Describe the impact of the COVID-19 pandemic on viral hepatitis prevention and control efforts, including elimination plans.

II. Identify strategies, including advocacy, to promote continued support for viral hepatitis prevention, control and elimination during the COVID-19 pandemic.

III. Characterize potential program and policy actions to integrate viral hepatitis prevention, control and elimination activities into the US COVID-19 response.
Speakers

Moderator:
Ronald O. Valdiserri MD, MPH
Professor, Rollins School of Public Health, Emory University

Alexander Billioux, MD, DPhil
Assistant Secretary for Health, Louisiana Dept. of Health

Boatemaa Ntiri-Reid, JD, MPH
Director of Hepatitis, National Alliance of State & Territorial AIDS Directors

Lauren Canary, MPH
Director, National Viral Hepatitis Roundtable
Louisiana’s Hepatitis C Subscription Model and Elimination Plan

Alexander Billioux, MD, DPhil, FACP
Assistant Secretary | Office of Public Health
Louisiana Department of Health

HepVu Webinar       June 2, 2020
Chronic Hepatitis C Update – Statewide Fact Sheet
Chronic Hepatitis C Update – Statewide Fact Sheet
Our big bet

Louisiana will eliminate Hepatitis C as a public health problem

2019
Establish Hepatitis C subscription model

2020
Treat 10,000 Louisianans in Medicaid and Corrections

2024
Treat 80% of Louisianans living with hepatitis C
Louisiana’s Hepatitis C Elimination Program

- Establish a Modified Hepatitis C Medication Subscription Model for Medicaid and Corrections
- Educate Public on Availability of Cure and Mobilize Priority Populations for Screenings
- Expand HCV Screening and Expedited Linkage to HCV Cure
- Strengthen HCV Surveillance to Link Persons Previously Diagnosed to Treatment
- Expand Provider Capacity to Treat Hepatitis C
- Implement Harm Reduction and Complementary Treatment Strategies
- Extend Elimination Efforts to All Populations Within the State
Trend in New Starts Post COVID-19

Number of Persons Who Started Treatment for HCV Through Medicaid/Corrections by Year/Month Treatment First Started - January 2019 to present

- Graph showing the trend in new starts post COVID-19.
Thank you!

Questions?

Alexander Billioux, M.D. D.Phil. FACP
Assistant Secretary
Louisiana Office of Public Health

Alexander.Billioux@la.gov
Assessing the COVID-19 Pandemic’s Impact on Health Department Viral Hepatitis Programs

Boatemaa Ntiri-Reid, JD, MPH
Director, Hepatitis

Impact of COVID-19 on Viral Hepatitis Programs
HepVu Webinar
June 2, 2020
Mission and Vision

NASTAD’s mission is to end the intersecting epidemics of HIV, viral hepatitis, and related conditions by strengthening domestic and global governmental public health through advocacy, capacity building, and social justice.

NASTAD’s vision is a world free of HIV and viral hepatitis.
Assessing COVID-19’s Programmatic Impact: NASTAD RFI
NASTAD COVID-19 RFI

- RFI disseminated to viral hepatitis, Ryan White HIV/AIDS Program, Part B/ADAP, and HIV prevention health department staff
- No. of Respondents: 55 Hepatitis; 49 HIV Prevention; 45 RWHAP, Part B/ADAP
- Key themes
  - Hepatitis and HIV capacity has been impacted across all programs as staff are detailed to COVID-19 response
  - Programs are struggling to continue to safely provide access to services, but are exploring innovative strategies, such as home testing, reconfigured SSP operations, and telehealth
  - Programs are beginning to integrate COVID-19 activities into hepatitis and HIV activities
  - Budget impact is difficult to predict; but many are predicting drops in state funding and other budget cuts
NASTAD COVID-19 RFI Results: Snapshot

Nearly **70%** of viral hepatitis programs stated that more funding for viral hepatitis surveillance and **77%** of RWHAP AIDS Drug Assistance Program (ADAP)/Part B Programs reported that more funding was needed for either ADAP or Part B.

**Over 80%** of HIV Prevention programs anticipate a decrease in program participation and retention and **93%** of hepatitis programs anticipate a reduction in outreach, education, testing, and linkage services.
40% of hepatitis programs, almost 60% of HIV prevention programs, and approximately 30% of AIDS Drug Assistance Programs receive funding from state general revenue funds.
Contact Information

Boatemaa Ntiri-Reid, JD, MPH  
Director, Hepatitis  
bntiri-reid@nastad.org

Hepatitis Team  
hepatitis@nastad.org

For additional information and resources, visit:  
https://www.nastad.org/resource/covid-19-updates-and-resources
Addressing Viral Hepatitis amid the COVID-19 pandemic

Lauren Canary, MPH (Epidemiologist, she/hers)
Director, National Viral Hepatitis Roundtable
Limitations to viral hepatitis response

- Outreach activities halted
- Lower rates of vaccination & testing
- Many syringe services programs scaled back
- Hepatitis A outbreak response under-resourced
- Viral hepatitis programs limited

Fewer cases identified and/or reported
Increased transmission?
Limitations to clinical care

- Viral hepatitis specialists in some jurisdictions overwhelmed with COVID-19 response
- Some not initiating treatment of HBV & HCV
- Labwork and/or liver staging geographically limited
- Patient risk-benefit decision making shift
- Provider education activities for viral hepatitis may be limited
Opportunities presented by COVID

- Greater appreciation for the impact of systemic racism on viral hepatitis outcomes
- Support vulnerable communities disproportionately impacted by both diseases
Mobilize and decentralize services

Mail-based services

Telemedicine

Mobile outreach

Virtual education
Bolster public health infrastructure

- Interest among all lawmakers in public health
- Funding for CDC & state/local health depts
- Increased interest in vaccination registries & EMR interoperability
- Investment in surveillance systems
- Decarceration & funding for correctional health services
- Development of novel testing methods
- Opportunity to use hep A outbreak lessons learned for COVID-19 vaccination
How is COVID-19 impacting your community?

Survey for patients, clinicians, community-based organizations, and public health available at

www.nvhr.org
Help us share what you are seeing with your elected officials.

Twitter: @nvhr1
#Voices4hep

For questions contact: Lauren@NVHR.org
Stay Tuned!

- Our next webinar will be on **Harm Reduction Services in the Time of COVID-19**, with
  - Tyler Bartholomew, Director of Research and Evaluation, The IDEA Exchange;
  - Dr. Don Des Jarlais, Associate Director, Infectious Disease Epidemiology and Theory Core, Center for Drug Use and HIV;
  - Daniel Raymond Deputy Director of Planning and Policy, Harm Reduction Coalition.

**Join us Thursday, June 11 at 2 pm ET.**
Learn more at HepVu.org

✉️ info@hepvu.org
🌟 HepVu
🐦 @HepVu

Subscribe to periodic updates at HepVu.org!
Questions?

Please submit your questions in the Q&A box. Thank you for joining!